{
    "thread": {
        "uuid": "26a9b2851337b01dcff38050a95ab1177539fd25",
        "url": "https://fintel.io/news/jp-morgan-downgrades-karuna-therapeutics-krtx-87",
        "site_full": "fintel.io",
        "site": "fintel.io",
        "site_section": "https://fintel.io/feed/news",
        "site_categories": [],
        "section_title": "Fintel News",
        "title": "JP Morgan Downgrades Karuna Therapeutics (KRTX)",
        "title_full": "JP Morgan Downgrades Karuna Therapeutics (KRTX)",
        "published": "2023-12-28T23:57:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "",
        "performance_score": 0,
        "domain_rank": 27145,
        "domain_rank_updated": "2023-12-26T12:06:20.000+02:00",
        "reach": null,
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "gplus": {
                "shares": 0
            },
            "pinterest": {
                "shares": 0
            },
            "linkedin": {
                "shares": 0
            },
            "stumbledupon": {
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "26a9b2851337b01dcff38050a95ab1177539fd25",
    "url": "https://fintel.io/news/jp-morgan-downgrades-karuna-therapeutics-krtx-87",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "George Maybach",
    "published": "2023-12-28T23:57:00.000+02:00",
    "title": "JP Morgan Downgrades Karuna Therapeutics (KRTX)",
    "text": "SHARE PRICE\nEXTENDED HOURS\n|Day's Range||-|\n|52 Week Range||-|\n|\n|\nJP Morgan Downgrades Karuna Therapeutics (KRTX)\nFintel reports that on December 28, 2023,\nJP Morgan\ndowngraded\ntheir\noutlook\nfor Karuna Therapeutics ( NasdaqGM:KRTX) from Overweight\nto Neutral\n.\nAnalyst Price Forecast Suggests 14.28% Downside\nAs of December 16, 2023,\nthe average one-year\nprice target for Karuna Therapeutics is 271.88.\nThe forecasts range from a low of 198.97 to a high of $336.00.\nThe average price target represents a decrease of 14.28% from its latest reported closing price of 317.16.\nSee our\nleaderboard of companies with the largest price target upside.\nThe projected annual revenue for Karuna Therapeutics\nis 23MM, an increase of 292.26%.\nThe projected annual non-GAAP\nEPS\nis -9.87.\nWhat is the Fund Sentiment?\nThere are\n711 funds or institutions reporting positions in Karuna Therapeutics.\nThis is a decrease\nof\n6\nowner(s) or 0.84% in the last quarter.\nAverage portfolio weight of all funds dedicated to KRTX is 0.35%,\na decrease\nof 9.16%.\nTotal shares owned by institutions increased\nin the last three months by 2.08% to 45,954K shares.\nThe put/call ratio of KRTX is 0.74, indicating a\nbullish\noutlook.\nWhat are Other Shareholders Doing?\nCapital International Investors holds 3,991K shares representing 10.58% ownership of the company. In it's prior filing, the firm reported owning 3,993K shares, representing a decrease of 0.05%. The firm decreased its portfolio allocation in KRTX by 18.04% over the last quarter.\nT. Rowe Price Investment Management holds 2,742K shares representing 7.27% ownership of the company. In it's prior filing, the firm reported owning 2,479K shares, representing an increase of 9.61%. The firm decreased its portfolio allocation in KRTX by 10.48% over the last quarter.\nPrice T Rowe Associates holds 2,735K shares representing 7.25% ownership of the company. In it's prior filing, the firm reported owning 2,661K shares, representing an increase of 2.68%. The firm decreased its portfolio allocation in KRTX by 15.74% over the last quarter.\nAGTHX - GROWTH FUND OF AMERICA holds 2,434K shares representing 6.45% ownership of the company. No change in the last quarter.\nSofinnova Investments holds 1,381K shares representing 3.66% ownership of the company. No change in the last quarter.\nKaruna Therapeutics Background Information\n(This description is provided by the company.)\nKaruna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.Karuna understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing itsextensive knowledge of neuroscience, the Company is harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives.\nStories by George Maybach\n[HC Wainwright & Co. Initiates Coverage of LM Funding America (LMFA) with Neutral Recommendation](/news/hc-wainwright-co-initiates-coverage-of-lm-funding-america-lmfa-with-neutral-recommendation-721)\nFintel reports that on December 28, 2023, HC Wainwright & Co.\n[HSBC Initiates Coverage of Travelers Companies (TRV) with Hold Recommendation](/news/hsbc-initiates-coverage-of-travelers-companies-trv-with-hold-recommendation-431)\nFintel reports that on December 28, 2023, HSBC initiated coverage of Travelers Companies (NYSE:TRV) with a Hold recommendation.\n[HSBC Initiates Coverage of American International Group (AIG) with Buy Recommendation](/news/hsbc-initiates-coverage-of-american-international-group-aig-with-buy-recommendation-635)\nFintel reports that on December 28, 2023, HSBC initiated coverage of American International Group (NYSE:AIG) with a Buy recommendation.\n[HSBC Initiates Coverage of Allstate (ALL) with Hold Recommendation](/news/hsbc-initiates-coverage-of-allstate-all-with-hold-recommendation-999)\nFintel reports that on December 28, 2023, HSBC initiated coverage of Allstate (NYSE:ALL) with a Hold recommendation.\n[HSBC Initiates Coverage of Chubb (CB) with Buy Recommendation](/news/hsbc-initiates-coverage-of-chubb-cb-with-buy-recommendation-667)\nFintel reports that on December 28, 2023, HSBC initiated coverage of Chubb (NYSE:CB) with a Buy recommendation.\n[HSBC Initiates Coverage of Progressive (PGR) with Hold Recommendation](/news/hsbc-initiates-coverage-of-progressive-pgr-with-hold-recommendation-646)\nFintel reports that on December 28, 2023, HSBC initiated coverage of Progressive (NYSE:PGR) with a Hold recommendation.\n[Saba Capital Income & Opportunities Fund (BRW) Declares $0.08 Dividend](/news/saba-capital-income-opportunities-fund-brw-declares-008-dividend-964)\nSaba Capital Income & Opportunities Fund said on December 22, 2023 that its board of directors declared a regular monthly dividend of $0.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
        "Health",
        "Economy, Business and Finance"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
        "persons": [],
        "organizations": [
            {
                "name": "jp morgan downgrades karuna therapeutics",
                "sentiment": "negative"
            },
            {
                "name": "karuna therapeutics",
                "sentiment": "none"
            }
        ],
        "locations": [
            {
                "name": "jp morgan",
                "sentiment": "none"
            },
            {
                "name": "karuna therapeutics",
                "sentiment": "none"
            }
        ]
    },
    "rating": null,
    "crawled": "2023-12-29T00:18:55.275+02:00",
    "updated": "2023-12-29T00:18:55.275+02:00"
}